Neutropenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Neutropenia is defined as an absolute neutrophil count (ANC) of less than 1500 per microliter (1500/microL). Severe neutropenia is defined as less than 500 per microliter (500/microL). The causes of primary defects of neutrophil function include failure of the following: Adhere to endothelial cells, Migrate into inflammation sites (abnormal chemotaxis), Ingest and kill bacteria, Produce microbicidal compounds to kill fungi and other pathogens, Form phagolysosomes, Make high concentrations of toxic reactive oxygen species.
·
In the United States, the prevalence of
neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5%
among black participants.
Thelansis’s “Neutropenia Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Neutropenia
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Neutropenia across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Neutropenia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment